Skip to main navigation
Athersys Inc.

Other menu

  • Home
  • Contact Us
  • Careers

Main Menu

  • About Us
    • About Us
    • Business Strategy
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • MultiStem Programs
    • MultiStem Programs
    • MultiStem Overview
    • Neurological
      • Ischemic Stroke
      • Other Neurological Indications
    • Cardiovascular
      • Acute Myocardial Infarction
      • Peripheral Vascular Disease
      • Congestive Heart Failure (CHF)
    • Inflammatory & Immune
      • Inflammatory Bowel Disease
      • GVHD
    • Other Programs
  • Clinical Programs
    • Clinical Programs
    • Overview
    • Neurological
    • Cardiovascular
    • Inflammatory & Immune
  • Other Programs
    • 5HT2c Agonist Program
      • Obesity
      • Schizophrenia
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
  • Media Center
    • Press Releases
    • Events & Presentations
    • In the News
    • Video
    • Social Media
    • Relevant Publications
    • Careers

top menu

  • Print
  • Share
Share this on: Close window
delicious Delicious
Digg Digg
Facebook Facebook
LinkedIn LinkedIn
Twitter Twitter

Media

Latest Press Releases

Apr 12, 2018

Athersys to Host First Quarter Financial Results Call

View All

Events & Presentations

Apr 12, 2018

GTCbio 15th Annual Stem Cell Summit

View All

In the News

Mar 26, 2018

Athersys and Healios look to accelerate Multistem's march in Asia - BioWorld

 

View All

Social Media

Athersys Inc @athersys
RT @G2Gconsulting: Great meetings for #BIOFLYIN2018 @IAmBiotech Thank you for your support @RepDaveJoyce @MikeTurnerOH @peggylehner for @Bi…
1 day ago

View All

 

Disruptors in Believeland

Time Is Precious

Committed to helping stroke patients

We are committed to developing safer and more effective therapeutic products that we believe represent substantial improvements over existing therapies, and that will create significant value for our shareholders.

Media menu

  • Press Releases
  • Events & Presentations
  • In the News
  • Video
  • Social Media
  • Relevant Publications

Footer

  • Contact Us
  • Credits
  • Sitemap
  • Policies
  • Legal Information
  • Industry Information

Other menu

  • Home
  • Contact Us
  • Careers

Main Menu

  • About Us
    • About Us
    • Business Strategy
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • MultiStem Programs
    • MultiStem Programs
    • MultiStem Overview
    • Neurological
    • Cardiovascular
    • Inflammatory & Immune
    • Other Programs
  • Clinical Programs
    • Clinical Programs
    • Overview
    • Neurological
    • Cardiovascular
    • Inflammatory & Immune
  • Other Programs
    • 5HT2c Agonist Program
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • SEC Filings
    • Stock Information
  • Media Center
    • Press Releases
    • Events & Presentations
    • In the News
    • Video
    • Social Media
    • Relevant Publications
    • Careers